Scholarlink

Background <p>Emerging evidence links immune activation to antidepressant response in adolescents with major depressive disorder (MDD). We examined how depressive symptoms, quality of life (QOL), and blood markers of inflammation, blood–brain barrier (BBB) integrity, and gut permeability change following antidepressant treatment in this population.</p> Methods <p>Twenty-six adolescents with MDD were evaluated at baseline (pre-treatment), 12 weeks, and 24 weeks after starting therapy. Depression and anxiety were measured by the Hamilton Depression Rating Scale (HAMD) and Hamilton Anxiety Rating Scale (HAMA). QOL was assessed with the QOL Scale for Children and Adolescents (QLSCA) and an adolescent social support instrument. Serum levels of IL-1β, TNF-α, IL-6, IL-4, S100β, claudin-5, LBP, I-FABP, and brain-derived neurotrophic factor (BDNF) were quantified.</p> Results <p>At baseline, pro-inflammatory cytokines (IL-1β, TNF-α, IL-6) and IL-4 strongly correlated with BBB (S100β, claudin-5) and gut-permeability (I-FABP) markers. IL-4 levels rose significantly and were associated with reduced anxiety (HAMA: <i>r</i> = −0.48, <i>p</i> &lt; 0.05) and better QOL (QLSCA: <i>r</i> = 0.57, <i>p</i> &lt; 0.01). BBB integrity and gut-permeability markers remained stable. In responders only, BDNF increased at 12 weeks (<i>p</i> &lt; 0.05) and IL-8 rose at 24 weeks (<i>p</i> &lt; 0.05), suggesting their involvement in treatment efficacy.</p> Conclusions <p>Antidepressant therapy in adolescents with MDD is accompanied by dynamic elevations in IL-4, IL-8, and BDNF that parallel clinical improvement and enhanced QOL. These biomarkers warrant further study to develop more targeted interventions for adolescent depression.</p> Clinical trial number <p>Not applicable.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

SSRI-induced modulation of cytokines, barrier permeability, and BDNF in adolescent depression

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月2日

查看全文
  • Wenhui Jiang,
  • Fengjie Gao,
  • Yajuan Fan,
  • Huanhuan Zhuo,
  • Boen Zhong,
  • Yue Cui,
  • Xiang Jiao,
  • Binglong Wen,
  • Ce Chen,
  • Jin Wu,
  • Kenji Hashimoto,
  • Xiancang Ma,
  • Yonghui Dang

摘要

Background

Emerging evidence links immune activation to antidepressant response in adolescents with major depressive disorder (MDD). We examined how depressive symptoms, quality of life (QOL), and blood markers of inflammation, blood–brain barrier (BBB) integrity, and gut permeability change following antidepressant treatment in this population.

Methods

Twenty-six adolescents with MDD were evaluated at baseline (pre-treatment), 12 weeks, and 24 weeks after starting therapy. Depression and anxiety were measured by the Hamilton Depression Rating Scale (HAMD) and Hamilton Anxiety Rating Scale (HAMA). QOL was assessed with the QOL Scale for Children and Adolescents (QLSCA) and an adolescent social support instrument. Serum levels of IL-1β, TNF-α, IL-6, IL-4, S100β, claudin-5, LBP, I-FABP, and brain-derived neurotrophic factor (BDNF) were quantified.

Results

At baseline, pro-inflammatory cytokines (IL-1β, TNF-α, IL-6) and IL-4 strongly correlated with BBB (S100β, claudin-5) and gut-permeability (I-FABP) markers. IL-4 levels rose significantly and were associated with reduced anxiety (HAMA: r = −0.48, p < 0.05) and better QOL (QLSCA: r = 0.57, p < 0.01). BBB integrity and gut-permeability markers remained stable. In responders only, BDNF increased at 12 weeks (p < 0.05) and IL-8 rose at 24 weeks (p < 0.05), suggesting their involvement in treatment efficacy.

Conclusions

Antidepressant therapy in adolescents with MDD is accompanied by dynamic elevations in IL-4, IL-8, and BDNF that parallel clinical improvement and enhanced QOL. These biomarkers warrant further study to develop more targeted interventions for adolescent depression.

Clinical trial number

Not applicable.